Tag
3 articles tagged Pharma Partnerships.
Chai Discovery is positioning AI protein design as a neutral software factory for pharma partners. The company has partnered with Eli Lilly, Pfizer, Novartis, and Argenx to accelerate antibody and binder discovery. Its visual design suite, compute infrastructure, and partner specific fine tuning create a platform model for precision drug engineering.
Genesis Molecular AI leaders discuss the strategic shift toward sub-angstrom precision, physics-informed synthetic data, and agentic workflows in drug discovery. The episode outlines how AI companies are commercializing through pharma partnerships, overcoming GPU bottlenecks, and redefining industry benchmarks for viable therapeutic development.
Analysis of Cellbricks' light-based bioprinting platform, dual-pipeline commercialization strategy, and regulatory arbitrage tactics. Explores how deep-tech startups leverage pharma co-development, milestone funding, and transatlantic operations to accelerate regenerative medicine market entry.
